HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A comparative approach between heterologous prime-boost vaccination strategy and DNA vaccinations for rabies.

AbstractBACKGROUND AND AIM:
Rabies is a widespread neurological zoonotic disease causing significant mortality rates, especially in developing countries. Although a vaccine for rabies is available, its production and scheduling are costly in such countries. Advances in recombinant DNA technology have made it a good candidate for an affordable vaccine. Among the proteins of rabies virus, the Glycoprotein (RVG) has been the major target for new vaccine development which plays the principal role in providing complete protection against RV challenge. The aim of this study is to produce recombinant RVG which could be a DNA vaccine candidate and to evaluate the efficiency of this construct in a prime-boost vaccination regimen, compared to commercial vaccine.
METHODS:
Cloning to pcDNA3.1(+) and expression of rabies virus glycoprotein gene in BSR cell  line were performed followed by SDS-PAGE and Western blot analysis of the expressed glycoprotein. The resulting genetic construct was used as a DNA vaccine by injecting 80 µg of the plasmid to MNRI mice twice. Prime-Boost vaccination strategy was performed using 80 µg plasmid construct as prime dose and the second dose of an inactivated rabies virus vaccine. Production of rabies virus neutralizing antibody (RVNA) titers of the serum samples were determined by RFFIT.
RESULTS:
In comparisons between heterologous prime-boost vaccination strategy and DNA vaccinations, the potency of group D that received Prime-Boost vaccine with the second dose of pcDNA3.1(+)-Gp was enhanced significantly compared to the group C which had received pcDNA3.1(+)-Gp as first injection.
CONCLUSION:
In this study, RVGP expressing construct was used in a comparative approach between Prime-Boost vaccination strategy and DNA vaccination and compared with the standard method of rabies vaccination. It was concluded that this strategy could lead to induction of acceptable humoral immunity.
AuthorsKiandokht Borhani, Mehdi Ajorloo, Taravat Bamdad, Sayed Hamid Reza Mozhgani, Mostafa Ghaderi, Ali Reza Gholami
JournalArchives of Iranian medicine (Arch Iran Med) Vol. 18 Issue 4 Pg. 223-7 (Apr 2015) ISSN: 1735-3947 [Electronic] Iran
PMID25841942 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antigens, Viral
  • Glycoproteins
  • Rabies Vaccines
  • Recombinant Proteins
  • Vaccines, DNA
  • Viral Envelope Proteins
  • glycoprotein G, Rabies virus
Topics
  • Animals
  • Antibodies, Neutralizing (blood)
  • Antibodies, Viral (blood)
  • Antigens, Viral (immunology)
  • Glycoproteins (genetics, immunology)
  • Immunization, Secondary
  • Mice
  • Rabies (prevention & control)
  • Rabies Vaccines (administration & dosage, immunology)
  • Rabies virus (immunology)
  • Recombinant Proteins (immunology)
  • Vaccination (methods)
  • Vaccines, DNA (administration & dosage, immunology)
  • Viral Envelope Proteins (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: